ETV6-NTRK3 is the defining fusion of mammary analogue secretory carcinoma (MASC) of saliv...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-NTRK-ETV6-SALIVARY |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-SALIVARY |
| Sources | SRC-FDA-CDS-2026 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-NTRK-FUSION |
|---|---|
| Variante | Fusion ETV6-NTRK3 |
| Maladie | DIS-SALIVARY |
| Niveau ESCAT | IA |
| Combinaisons recommandées | larotrectinib monotherapy, entrectinib monotherapy |
| Résumé des faits | ETV6-NTRK3 is the defining fusion of mammary analogue secretory carcinoma (MASC) of salivary gland. Larotrectinib and entrectinib are highly active (NAVIGATE / STARTRK-2 pooled — ORR 75-90% in salivary cohort). Treatment is identical to gene-level NTRK fusion. |
Notes
ESCAT IA. OncoKB Level 1. Fusion-partner-specific cell maintained for completeness. ETV6-NTRK3 also drives infantile fibrosarcoma, congenital mesoblastic nephroma, and a fraction of secretory breast carcinoma — separate BMA cells per disease.
Utilisé par
No reverse references found in the YAML corpus.